{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:47:01Z","timestamp":1786981621696,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11126-021-09892-0","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:02:20Z","timestamp":1617883340000},"page":"1413-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder"],"prefix":"10.1007","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-1265","authenticated-orcid":false,"given":"Shabir Ahmad","family":"Dar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayees Ahmad","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inaamul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"9892_CR1","volume-title":"Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder","author":"LM Koran","year":"2013","unstructured":"Koran LM, Simpson HB. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington: American Psychiatric Association; 2013."},{"issue":"3","key":"9892_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0193-953X(05)70177-5","volume":"23","author":"LM Koran","year":"2000","unstructured":"Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am. 2000;23(3):509\u201317.","journal-title":"Psychiatr Clin N Am"},{"key":"9892_CR3","unstructured":"American Psychiatric Association. American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006. American Psychiatric Pub. 2006. https:\/\/psychiatryonline.org\/guidelines. Accessed 09.12.20."},{"issue":"S14","key":"9892_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S1092852900026924","volume":"13","author":"B Bandelow","year":"2008","unstructured":"Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr. 2008;13(S14):37\u201346.","journal-title":"CNS Spectr"},{"issue":"1","key":"9892_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","volume":"52","author":"JW Jefferson","year":"1995","unstructured":"Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry. 1995;52(1):53\u201360.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"9892_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881105059253","volume":"19","author":"DS Baldwin","year":"2005","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567\u201396.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"9892_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ. WFSBP task force on treatment guidelines for anxiety obsessive-compulsive post-traumatic stress disorders, Bandelow B, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders\u2013first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"9892_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/16506070510043750","volume":"34","author":"J Cottraux","year":"2005","unstructured":"Cottraux J, Bouvard MA, Milliery M. Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther. 2005;34(3):185\u201392.","journal-title":"Cogn Behav Ther"},{"issue":"8","key":"9892_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1017\/S1461145711001829","volume":"15","author":"NA Fineberg","year":"2012","unstructured":"Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012;15(8):1173\u201391.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"9892_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9892_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4088\/JCP.v65n0106","volume":"65","author":"D Denys","year":"2004","unstructured":"Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004;65:37\u201343.","journal-title":"J Clin Psychiatry"},{"key":"9892_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"CJ McDougle","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine refractory obsessive\u2013compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"9892_CR13","first-page":"794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive\u2013compulsive disorder. Arch. Gen. Psychiatry. 2000;57:794\u2013801.","journal-title":"Psychiatry"},{"key":"9892_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","volume":"15","author":"S Erzegovesi","year":"2005","unstructured":"Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low dose augmentation of fluvoxamine treatment in obsessive\u2013 compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15:69\u201374.","journal-title":"Eur Neuropsychopharmacol"},{"key":"9892_CR15","first-page":"CD0054473","volume":"18","author":"JC Ipser","year":"2006","unstructured":"Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;18:CD0054473.","journal-title":"Cochrane Database Syst Rev"},{"key":"9892_CR16","doi-asserted-by":"publisher","first-page":"79Y93","DOI":"10.1016\/j.euroneuro.2006.07.002","volume":"17","author":"P Skapinakis","year":"2007","unstructured":"Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17:79Y93.","journal-title":"Eur Neuropsychopharmacol"},{"key":"9892_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","volume":"19","author":"G Goodwin","year":"2009","unstructured":"Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009;19:520\u201332.","journal-title":"Eur Neuropsychopharmacol"},{"key":"9892_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1176\/appi.ps.54.8.1111","volume":"54","author":"A Kaplan","year":"2003","unstructured":"Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv. 2003;54:1111\u20138.","journal-title":"Psychiatr Serv"},{"key":"9892_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/10673220216215","volume":"10","author":"M McDonough","year":"2002","unstructured":"McDonough M, Kennedy N. Pharmacological management of obsessive-compulsive disorder: a review for clinicians. Harv Rev Psychiatry. 2002;10:127\u201337.","journal-title":"Harv Rev Psychiatry"},{"key":"9892_CR20","first-page":"63","volume":"5","author":"M Passeri","year":"1993","unstructured":"Passeri M, Cucinotta D, Abate G, et al. Oral 5\u2032-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993;5:63\u201371.","journal-title":"Aging (Milano)"},{"key":"9892_CR21","first-page":"19","volume":"8","author":"LD Ginsberg","year":"2011","unstructured":"Ginsberg LD, Oubre AY, Daoud YA. l-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode. Innov Clin Neurosci. 2011;8:19\u201328.","journal-title":"Innov Clin Neurosci"},{"key":"9892_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1176\/appi.ajp.2012.11071114","volume":"169","author":"G Papakostas","year":"2012","unstructured":"Papakostas G, et al. l-methylfolate adjunctive therapy for selective serotonin reuptake inhibitors (SSRIs) for major depressive disorder: results of 2 randomized, double-blind trials. Am J Psychiatry. 2012;169:1267\u201374.","journal-title":"Am J Psychiatry"},{"key":"9892_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1017\/S1092852900015418","volume":"12","author":"SM Stahl","year":"2007","unstructured":"Stahl SM. Novel therapies for depression: L-methylfolate as a trimonoamine modulator and antidepressant agent. CNS Spectr. 2007;12:739\u201344.","journal-title":"CNS Spectr"},{"issue":"7","key":"9892_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.drudis.2007.12.009","volume":"13","author":"AW Goddard","year":"2008","unstructured":"Goddard AW, et al. Serotoninergic mechanisms in the treatment of obsessive\u2013compulsive disorder. Drug Discov Today. 2008;13(7):325\u201332.","journal-title":"Drug Discov Today"},{"issue":"2","key":"9892_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0165-1781(02)00012-4","volume":"109","author":"S Moritz","year":"2002","unstructured":"Moritz S, Meier B, Kloss M, Jacobsen D, Wein C, Fricke S, et al. Dimensional structure of the Yale-Brown obsessive-compulsive scale (Y-BOCS). Psychiatry Res. 2002;109(2):193\u20139.","journal-title":"Psychiatry Res"},{"issue":"1\u20133","key":"9892_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.schres.2010.10.024","volume":"126","author":"P Masand","year":"2011","unstructured":"Masand P, O'Gorman C, Mandel FS. Clinical global impression of improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res. 2011;126(1\u20133):174\u201383.","journal-title":"Schizophr Res"},{"issue":"7","key":"9892_CR27","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.","journal-title":"Psychiatry (Edgmont)"},{"key":"9892_CR28","doi-asserted-by":"publisher","unstructured":"Lingj\u00e6rde O, Ahlfors, UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica. 1987;76(Suppl 334):100. https:\/\/doi.org\/10.1111\/j.1600-0447.1987.tb10566.x.","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"9892_CR29","unstructured":"Armitage P, Berry G, Matthews JN. Statistical methods in medical research. 4th ed.\u00a0John Wiley & Sons. Inc., New York. 1971:362\u20135."},{"key":"9892_CR30","volume-title":"IBM SPSS statistics for windows, Version 23.0","author":"IB Crop","year":"2015","unstructured":"Crop IB. IBM SPSS statistics for windows, Version 23.0. IBM Crop: Armonk; 2015."},{"issue":"5","key":"9892_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","volume":"18","author":"G Maina","year":"2008","unstructured":"Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364\u201372.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"9892_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0278-5846(03)00050-2","volume":"27","author":"G D'Amico","year":"2003","unstructured":"D'Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):619\u201323.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"9892_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","volume":"31","author":"MR Muscatello","year":"2011","unstructured":"Muscatello MR, Bruno A, Pandolfo G, Mic\u00f2 U, Scimeca G, Romeo VM, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31(2):174\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"9892_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","volume":"55","author":"NA Shapira","year":"2004","unstructured":"Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P. Goodman WK. a double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55(5):553\u20135.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"9892_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/YIC.0b013e32832e9b91","volume":"24","author":"E Pessina","year":"2009","unstructured":"Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24(5):265\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"9892_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/15622970903418544","volume":"11","author":"B Dell\u2019Osso","year":"2010","unstructured":"Dell\u2019Osso B, Buoli M, Hollander E, Altamura AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive\u2013compulsive disorder. World J Biol Psychiatry. 2010;11(1):59\u201365.","journal-title":"World J Biol Psychiatry"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-021-09892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11126-021-09892-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-021-09892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T03:22:04Z","timestamp":1634786524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11126-021-09892-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9892"],"URL":"https:\/\/doi.org\/10.1007\/s11126-021-09892-0","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"31 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The consent document and the research Protocols were approved by the institutional ethics committee of Govt. Medical College Srinagar (IEC\/GMCS\/211\/17). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}